Elizabeth Tucker

Elizabeth Vitucci serves as a key procurement professional within the National Cancer Institute (NCI), supporting the agency’s mission to accelerate cancer research through advanced scientific infrastructure and diagnostic innovation. She manages a diverse portfolio of acquisitions focused on high-complexity laboratory systems, analytical instrumentation, and specialized testing services critical to genomic and molecular research. Her work ensures that NCI’s research ecosystem is equipped with cutting-edge technologies and reliable analytical capabilities, aligning procurement strategy with the Institute’s translational science priorities. She typically handles complex, performance-based contracts under FAR Part 15, often involving technical evaluations and multi-criteria source selection processes. Vitucci maintains strong, recurring relationships with Roche Diagnostics Corporation, a primary supplier of precision diagnostics and laboratory instrumentation. Her contracting patterns reflect a preference for established industry leaders with proven capabilities in clinical-grade analytical platforms, though she also engages with niche vendors offering specialized testing services and custom assay development. These partnerships are characterized by long-term performance reliability, technical compliance with regulatory standards, and adherence to quality management systems such as ISO 13485. Her contracting activity shows a strong preference for unrestricted competitions, with 87.7% of awards issued without set-aside restrictions. While small business participation is present at 12.3%, it is primarily through Total Small Business Set-Asides under FAR 19.5, indicating a focus on capability-driven sourcing rather than socioeconomic preferences like 8(a), HUBZone, or SDVOSB programs. Her primary NAICS focus is on 334516 (Analytical Laboratory Instrument Manufacturing) and 541380 (Testing Laboratories and Services), reflecting deep expertise in procuring next-generation sequencing platforms, mass spectrometers, flow cytometers, and associated validation and calibration services. She routinely sources technologies supporting precision oncology, biomarker discovery, and high-throughput data generation, ensuring NCI’s research infrastructure remains at the forefront of cancer diagnostics innovation.